A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

Inclusion Criteria: * Males and females between 18 and 60 years of age * Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential. Furthermore, female subjects must not have been pregnant from at least three months prior to enter in the study * Subjects have RMS according to the revised McDonald Criteria (2010) * Subjects with an expanded disability status scale (EDSS) score of less than 6.0 * Subjects naive to treatment and eligible for treatment with Rebif® 44 three times a week, or patients having received glatiramer acetate with a wash-out from at least one month, or patients having received treatment with natalizumab or fingolimod with a wash-out from at least three months * Subjects able to self-inject treatment using RebiSmart® * Subjects willing and able to comply with the protocol for the duration of the study * Subjects have given written informed consent to take part in the study Exclusion Criteria: * Subjects have any disease other than MS that could better explain his/her signs and symptoms * Subjects who have received any immunosuppressive agents within 3 months prior to Baseline * Subjects who have received any corticosteroids within 30 days prior to Baseline * Subjects have a MS relapse within 30 days prior to Baseline * Subjects have inadequate liver function and bone marrow reserve as defined in the protocol * Subjects have moderate to severe renal impairment * Subjects have any visual or physical impairment that p…